Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

Author's Avatar
Jun 08, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership changes to strengthen the Company’s alignment around the development of its late-stage ophthalmology product portfolio. The realignment was affected to enhance Ocular’s ability to execute its strategy of building a comprehensive portfolio of assets to treat a broad range of ocular surface and back-of-the-eye retina diseases.